Skip to main content

26 October 2021

OXGENE Case Study - TiCARos

Download PDF – 1.4 MB

TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of next generation immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built a team with a deep passion for innovative science and immunology. Their strength is in leading-edge approaches to new CAR-T cell therapies. Since its foundation, TiCARos has established active collaborations with the renowned institutions Seoul National University College of Medicine and National Cancer Center, with which their founders have strong ties.

Download the resource to continue reading.